Decheng Capital Management III (Cayman)’s 10x Genomics TXG Stock Holding History

Decheng Capital Management III (Cayman)’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$14.8M	Hold	359,554	–	–	4.95%	7
2023 Q2	$20.1M	Hold	359,554	–	–	6.3%	4
2023 Q1	$20.1M	Hold	359,554	–	–	8.09%	3
2022 Q4	$13.1M	Hold	359,554	–	–	4.9%	8
2022 Q3	$10.2M	Buy	359,554 +55,570	+18%	+$2.12M	3.71%	8
2022 Q2	$13.8M	Hold	303,984	–	–	5.22%	6
2022 Q1	$23.1M	Buy	+303,984	New	+$26.6M	7.09%	5

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Decheng Capital Management III (Cayman)'s TXG Position: Q3 2023 in Review

Decheng Capital Management III (Cayman) held its 10x Genomics (TXG) position steady in Q3 2023 at 359,554 shares worth $14.8M. The position accounts for 4.95% of the portfolio, ranked #7.

Decheng Capital Management III (Cayman) first reported a position in TXG in Q1 2022 and has held it in 7 quarters since. The position peaked at $23.1M in Q1 2022. 256 funds tracked by Wall St. Rank hold TXG as of Q3 2023.

Decheng Capital Management III (Cayman) held 359,554 shares of 10x Genomics worth $14.8M as of Q3 2023.
Decheng Capital Management III (Cayman) left its 10x Genomics share count unchanged in Q3 2023.
10x Genomics made up 4.95% of Decheng Capital Management III (Cayman)'s portfolio in Q3 2023, its #7 holding.
Decheng Capital Management III (Cayman) first reported a position in 10x Genomics in Q1 2022 and has held it in 7 quarters since.
Decheng Capital Management III (Cayman)'s 10x Genomics position peaked at $23.1M in Q1 2022.
256 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2023.

Based on Decheng Capital Management III (Cayman)'s 13F filing for Q3 2023, filed 13 Nov 2023.